X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare STRIDES PHARMA SCIENCE with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs DIVIS LABORATORIES - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE DIVIS LABORATORIES STRIDES PHARMA SCIENCE/
DIVIS LABORATORIES
 
P/E (TTM) x 15.5 31.3 49.4% View Chart
P/BV x 0.9 7.1 13.0% View Chart
Dividend Yield % 0.5 0.6 83.6%  

Financials

 STRIDES PHARMA SCIENCE   DIVIS LABORATORIES
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
DIVIS LABORATORIES
Mar-18
STRIDES PHARMA SCIENCE/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,1471,142 100.5%   
Low Rs642533 120.4%   
Sales per share (Unadj.) Rs317.2146.6 216.4%  
Earnings per share (Unadj.) Rs7.833.0 23.7%  
Cash flow per share (Unadj.) Rs25.138.4 65.2%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.21.2 18.7%  
Book value per share (Unadj.) Rs274.3222.8 123.1%  
Shares outstanding (eoy) m89.50265.47 33.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.85.7 49.4%   
Avg P/E ratio x114.025.3 449.8%  
P/CF ratio (eoy) x35.721.8 163.7%  
Price / Book Value ratio x3.33.8 86.8%  
Dividend payout %25.530.3 84.2%   
Avg Mkt Cap Rs m80,058222,318 36.0%   
No. of employees `0002.510.8 23.3%   
Total wages/salary Rs m4,3414,561 95.2%   
Avg. sales/employee Rs Th11,325.83,616.0 313.2%   
Avg. wages/employee Rs Th1,731.4423.8 408.6%   
Avg. net profit/employee Rs Th280.1814.9 34.4%   
INCOME DATA
Net Sales Rs m28,39438,915 73.0%  
Other income Rs m9411,134 82.9%   
Total revenues Rs m29,33440,049 73.2%   
Gross profit Rs m3,96512,617 31.4%  
Depreciation Rs m1,5401,425 108.1%   
Interest Rs m1,96213 14,754.9%   
Profit before tax Rs m1,40312,313 11.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m973,543 2.7%   
Profit after tax Rs m7028,770 8.0%  
Gross profit margin %14.032.4 43.1%  
Effective tax rate %6.928.8 24.1%   
Net profit margin %2.522.5 11.0%  
BALANCE SHEET DATA
Current assets Rs m24,83645,351 54.8%   
Current liabilities Rs m18,9936,507 291.9%   
Net working cap to sales %20.699.8 20.6%  
Current ratio x1.37.0 18.8%  
Inventory Days Days71127 56.0%  
Debtors Days Days11395 119.2%  
Net fixed assets Rs m34,28921,160 162.0%   
Share capital Rs m895531 168.6%   
"Free" reserves Rs m23,65158,625 40.3%   
Net worth Rs m24,54659,156 41.5%   
Long term debt Rs m15,5130-   
Total assets Rs m65,43767,832 96.5%  
Interest coverage x1.7926.8 0.2%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.6 75.6%   
Return on assets %4.112.9 31.4%  
Return on equity %2.914.8 19.3%  
Return on capital %6.920.8 33.1%  
Exports to sales %00-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m15,69732,359 48.5%   
Fx outflow Rs m7359,042 8.1%   
Net fx Rs m14,96223,317 64.2%   
CASH FLOW
From Operations Rs m1,8717,759 24.1%  
From Investments Rs m5,826-4,783 -121.8%  
From Financial Activity Rs m-10,157-3,142 323.3%  
Net Cashflow Rs m-2,615-166 1,575.2%  

Share Holding

Indian Promoters % 27.7 52.0 53.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 11.8 320.3%  
FIIs % 8.6 19.0 45.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 17.2 150.6%  
Shareholders   56,241 31,796 176.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   PLETHICO PHARMA  AJANTA PHARMA  UNICHEM LAB  ALKEM LABORATORIES  ELDER PHARMA  

Compare STRIDES PHARMA SCIENCE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Falling Stocks, Tumbling Rupee and Weakening Economy(Podcast)

Another week of slowdown in the markets over fears of a looming slowdown in the domestic and global economy continue.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Interest Rates Are Low. Buy Solid Dividend Stocks Instead(The 5 Minute Wrapup)

Aug 13, 2019

The dividends paid by these stocks are helpful when interest rates are falling.

My Top 3 Dividend Stocks to Buy Now(Profit Hunter)

Aug 19, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

Chandrayaan 2 Heads to the Moon and It's Good News for These Stocks(The 5 Minute Wrapup)

Aug 14, 2019

Why investors should take note of India's advantage as a low cost satellite launcher...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Aug 23, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 8-QTR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS